Report of specific cardiovascular outcomes of the ADVANTAGE trial

被引:6
作者
Braunstein, N [1 ]
Polis, A [1 ]
机构
[1] Merck & Co Inc, Rahway, NJ 07065 USA
关键词
D O I
10.7326/0003-4819-143-2-200507190-00118
中图分类号
R5 [内科学];
学科分类号
1002 ; 100201 ;
摘要
引用
收藏
页码:158 / 159
页数:2
相关论文
共 5 条
[1]   COLLABORATIVE OVERVIEW OF RANDOMIZED TRIALS OF ANTIPLATELET THERAPY .1. PREVENTION OF DEATH, MYOCARDIAL-INFARCTION, AND STROKE BY PROLONGED ANTIPLATELET THERAPY IN VARIOUS CATEGORIES OF PATIENTS [J].
ALTMAN, R ;
CARRERAS, L ;
DIAZ, R ;
FIGUEROA, E ;
PAOLASSO, E ;
PARODI, JC ;
CADE, JF ;
DONNAN, G ;
EADIE, MJ ;
GAVAGHAN, TP ;
OSULLIVAN, EF ;
PARKIN, D ;
RENNY, JTG ;
SILAGY, C ;
VINAZZER, H ;
ZEKERT, F ;
ADRIAENSEN, H ;
BERTRANDHARDY, JM ;
BRAN, M ;
DAVID, JL ;
DRICOT, J ;
LAVENNEPARDONGE, E ;
LIMET, R ;
LOWENTHAL, A ;
MORIAU, M ;
SCHAPIRA, S ;
SMETS, P ;
SYMOENS, J ;
VERHAEGHE, R ;
VERSTRAETE, M ;
ATALLAH, A ;
BARNETT, H ;
BATISTA, R ;
BLAKELY, J ;
CAIRNS, JA ;
COTE, R ;
CROUCH, J ;
EVANS, G ;
FINDLAY, JM ;
GENT, M ;
LANGLOIS, Y ;
LECLERC, J ;
NORRIS, J ;
PINEO, GF ;
POWERS, PJ ;
ROBERTS, R ;
SCHWARTZ, L ;
SICURELLA, J ;
TAYLOR, W ;
THEROUX, P .
BMJ-BRITISH MEDICAL JOURNAL, 1994, 308 (6921) :81-100
[2]  
*FDA ADV COMM BACK, 2001, ARTHR ADV COMM 8 FEB
[3]   Cardiovascular thrombotic events in controlled, clinical trials of rofecoxib [J].
Konstam, MA ;
Weir, MR ;
Reicin, A ;
Shapiro, D ;
Sperling, RS ;
Barr, E ;
Gertz, BJ .
CIRCULATION, 2001, 104 (19) :2280-2288
[4]   Gastrointestinal tolerability and effectiveness of rofecoxib versus naproxen in the treatment of osteoarthritis - A randomized, controlled trial [J].
Lisse, JR ;
Perlman, M ;
Johansson, G ;
Shoemaker, JR ;
Schechtman, J ;
Skalky, CS ;
Dixon, ME ;
Polls, AB ;
Mollen, AJ ;
Geba, GP .
ANNALS OF INTERNAL MEDICINE, 2003, 139 (07) :539-546
[5]   Selective COX-2 inhibition and cardiovascular effects: A review of the rofecoxib development program [J].
Weir, MR ;
Sperling, RS ;
Reicin, A ;
Gertz, BJ .
AMERICAN HEART JOURNAL, 2003, 146 (04) :591-604